Verified Nov 2026
Batteries & E-Mobility
·

San Carlos, California
·
Since 2013
Vaxcyte is a clinical-stage vaccine development company founded in 2013 and headquartered in San Carlos, California, with 500–1,000 employees. The company engineers broad-spectrum conjugate and novel protein vaccines targeting bacterial infectious diseases including pneumococcal disease, Group A Strep, and Shigella. It serves medical, military-defense, and industrial sectors using its proprietary cell-free protein synthesis platform called XpressCF.
Vaxcyte at a glance
Employees
500-1,000
Founded
2013
Headquarters
San Carlos, California
Industries
Automotive
Electric Vehicles
Medical
Military & Defense
Industrial Equipment
Overview
Vaxcyte is a clinical-stage vaccine development company founded in 2013 and headquartered in San Carlos, California, with 500–1,000 employees. The company engineers broad-spectrum conjugate and novel protein vaccines targeting bacterial infectious diseases including pneumococcal disease, Group A Strep, and Shigella. It serves medical, military-defense, and industrial sectors using its proprietary cell-free protein synthesis platform called XpressCF.
At a glance
Attribute | Detail |
|---|---|
Founded | 2013 |
Headquarters | San Carlos, California |
Employees | 500-1,000 |
Primary capability | Batteries & E-Mobility |
What Vaxcyte makes
The company operates a proprietary XpressCF cell-free protein synthesis platform that enables efficient creation of complex protein antigens and optimized protein carriers for vaccine development.
Latest developments
2026-11-04 — Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update - Vaxcyte, Inc. (vaxcyte.com)
2026-02-24 — Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Vaxcyte, Inc. (vaxcyte.com)
2026-02-02 — Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Vaxcyte, Inc. (vaxcyte.com)
2025-11-04 — Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine | S-GE (s-ge.com)
2025-11-04 — Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study - Vaxcyte, Inc. (vaxcyte.com)
Facilities
Vaxcyte is headquartered in San Carlos, California. Public sources also reference these locations:
Visp, Switzerland — sec.gov
Company details
Vaxcyte has contracted with Lonza to expand manufacturing capacity in Visp, Switzerland for its pneumococcal conjugate vaccine candidate VAX-31. Vaxcyte was founded in 2013, has an estimated 500-1,000 employees, and is headquartered in San Carlos, California.
Frequently asked questions
What does Vaxcyte make?
Vaxcyte is a clinical-stage vaccine development company founded in 2013 and headquartered in San Carlos, California, with 500–1,000 employees. The company engineers broad-spectrum conjugate and novel protein vaccines targeting bacterial infectious diseases including pneumococcal disease, Group A Strep, and Shigella. It serves medical, military-defense, and industrial sectors using its proprietary cell-free protein synthesis platform called XpressCF.
Where is Vaxcyte headquartered?
Vaxcyte is headquartered in San Carlos, California (825 Industrial Rd, San Carlos, California, 94070-3312).
When was Vaxcyte founded?
Vaxcyte was founded in 2013.
How big is Vaxcyte?
Vaxcyte has an estimated 500-1,000 employees.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
